相关临床试验
2699
184 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
28
1.0%
No Longer Available
23
0.8%
终止
371
13.8%
招募中
183
6.8%
Approved For Marketing
2
0.1%
Available
16
0.6%
撤回
95
3.5%
进行中（未招募）
156
5.8%
Unknown
3
0.1%
已完成
1822
67.5%
暂无批准数据
- The Huntington's disease treatment market across the 7MM was valued at approximately USD 320 million in 2025 and is projected to grow at a 14% CAGR from 2026 to 2036. - Skyhawk Therapeutics' SKY-0515 demonstrated a 62% dose-dependent reduction in mutant huntingtin protein at the 9 mg dose in a nine-month interim analysis, with Phase II/III FALCON-HD now enrolling globally. - UniQure's AMT-130 gene therapy met its Phase I/II primary endpoint, significantly slowing symptom progression, and the company plans to file an MAA with the UK MHRA in Q3 2026. - Current treatments including AUSTEDO, INGREZZA, and generic tetrabenazine remain focused on symptomatic relief, underscoring the unmet need for disease-modifying interventions.
- The American Society of Clinical Oncology has expanded its TAPUR Study to include fam-trastuzumab deruxtecan-nxki, marking the first antibody-drug conjugate addition to the precision medicine trial platform. - The study will evaluate the ADC's effectiveness in solid tumors with HER2 gene amplification and non-small cell lung cancer with HER2 IHC2+/3+ expression. - TAPUR also added the dabrafenib plus trametinib combination therapy to generate additional post-market data for BRAF V600E mutation-positive solid tumors. - The expanded study aims to broaden patient populations eligible for these targeted therapies while providing manufacturers with regulatory-quality safety and efficacy data.
- Pacira BioSciences appointed Samit Hirawat, M.D., former Chief Medical Officer at Bristol Myers Squibb, to its Board of Directors, expanding the board to 10 members. - Dr. Hirawat brings over 25 years of clinical development expertise, having previously overseen worldwide clinical development portfolios at Bristol Myers Squibb and served as Head of Oncology Development at Novartis. - The appointment comes as Pacira advances its pipeline of non-opioid pain therapies, including PCRX-201, a novel gene therapy in Phase 2 development for osteoarthritis of the knee. - Pacira currently markets three commercial-stage non-opioid treatments: EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis knee pain, and iovera for drug-free pain control.
- WRN inhibitors represent a fast-emerging precision oncology segment targeting DNA repair vulnerabilities in microsatellite instability-high (MSI-H) tumors through synthetic lethality mechanisms. - Multiple promising candidates including NDI-219216, GSK4418959, HRO761, and RO7589831 are advancing through early-stage clinical trials, demonstrating potent anti-tumor activity and strong selectivity for MSI tumors. - The market is expected to surge significantly by 2040, driven by advances in biomarker-driven patient stratification and compelling preclinical data showing tumor regression in patient-derived xenograft models. - Leading pharmaceutical companies including Nimbus Therapeutics, GlaxoSmithKline, Ideaya Biosciences, and Novartis are developing these novel therapies for colorectal, endometrial, and other solid tumors.
- Patients with chronic spontaneous urticaria (CSU) experience significantly worse quality of life and higher healthcare utilization compared to those with atopic dermatitis and psoriasis, according to real-world data from 74,994 survey respondents. - CSU patients reported the lowest mental and physical health scores among inflammatory skin conditions, with dermatology-related quality of life scores more than double those of atopic dermatitis and psoriasis patients. - Despite having higher rates of full-time employment and university degrees, CSU patients were least likely to receive treatment and experienced nearly three times higher work absenteeism rates. - Global research confirms that 84% of CSU patients treated with H1 antihistamines have inadequate disease control, driving many to seek alternative therapies including psychological support, homeopathy, and acupuncture.
- Quetzal Therapeutics officially launched with $50 million in committed capital to develop transformative therapies for rare and life-threatening diseases. - The company's lead candidate QTX-2101 is a novel oral arsenic trioxide therapy for Acute Promyelocytic Leukemia expected to enter Phase III trials by late 2025. - QTX-2101 is supported by encouraging comparative pharmacokinetic data from a Phase 1b trial previously sponsored by Syros Pharmaceuticals. - The company is led by experienced pharmaceutical executives and guided by an accomplished board including oncology drug development experts.
- Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics. - The inFoods IBS test demonstrated statistically significant efficacy in a multicenter clinical study published in Gastroenterology, with 59.6% of patients achieving FDA endpoints for abdominal pain reduction compared to 42.2% in the control group. - Madel will focus on strategic partnerships, payer strategy development, and scaling domestic and global provider engagement for the diagnostic-guided therapy that identifies patient-specific food triggers for IBS symptoms. - The test represents the only targeted therapy to demonstrate efficacy specifically in IBS-M patients, a historically underserved subgroup, according to the clinical study conducted at leading institutions including Cleveland Clinic and Mayo Clinic.
- DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment. - Merck's KEYNOTE-811 Phase III trial achieved its dual primary endpoint of overall survival in July 2024, evaluating Keytruda combination therapy for first-line treatment. - ENHERTU received US approval in April 2024 as the first tumor-agnostic HER2-targeted therapy for metastatic HER2-positive solid tumors. - Leading pipeline candidates include SHR-A1811 from Jiangsu HengRui Medicine, Cinrebafusp alfa from Pieris Pharmaceuticals, and BI-1607 from BioInvent International.
- The first patient worldwide has been treated with Remibrutinib, a novel B-cell targeting therapy for Myasthenia Gravis, marking the start of an international Phase III clinical trial at HonorHealth Research Institute. - This represents the first time a drug has targeted B cells in Myasthenia Gravis treatment, offering a new mechanism of action that blocks a different part of the neuro-muscular-junction pathway than existing therapies. - The rare autoimmune disease affects fewer than 200 people per million, causing muscle weakness symptoms that severely impact daily activities like brushing teeth and getting dressed. - If successful, the trial could lead to FDA approval for Remibrutinib in Myasthenia Gravis, with the drug already approved for certain cancer types.
- Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapeutics. - Conkling previously led commercial organizations at Rafael Holdings, Immunomedics, and Novartis, including the successful launch of Trodelvy for triple negative breast cancer and Kymriah CAR-T therapy. - The appointment positions Protara for potential transition to a commercial-stage organization as it advances TARA-002 for bladder cancer and lymphatic malformations through Phase 2 trials.
